Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. - Bye AP; Kriek N; Sage T; Rawlings SJ; Prodger C; Kesavan M; Lees C; Booth S; Cowen LG; Shefferd K; Desborough MJ; Gibbins JM; et al. (Haematologica, 2023)